EMD Serono recently named Miguel Fernandez Alcalde as its new president. The new executive spoke with Pharmaceutical ...

The clinical hold is due to questions about BX004’s nebulizer device, temporarily pausing US enrollment in the cystic ...

The regulatory body determined that PTC Therapeutics’ New Drug Application for vatiquinone did not provide sufficient ...

The MFN executive order introduces uncertainty in pharma pricing strategies, necessitating careful risk assessment and ...

Pharm Exec unveils its new slate of rising leaders in the biopharma industry—profiling the stories of five executives ...

The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

Ron Lanton, partner, Lanton Law, warns that ongoing lawsuits targeting vaccine policy could create ripple effects across FDA ...

Rob Abbott, CEO, ISPOR, highlights how uniting regulators, payers, and academic leaders worldwide can accelerate access to innovative treatments and strengthen evidence-based healthcare.

The disease doesn’t have any FDA approved treatments, leaving families desperate for FDA to approve the treatment.

The collaboration will explore RNA-based small molecule drug candidates aimed at neurological conditions where existing ...

Recent advancements in COPD treatments are providing patients with potential new first-line treatments. Pharmaceutical ...

NIH's new strategy emphasizes transparency, prioritizes urgent health needs, and shifts focus to domestic research and ...